A Phase I,II Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of Single Doses of TT-034 for Subjects With Chronic Hepatitis C (CHC) Infection
Phase of Trial: Phase I/II
Latest Information Update: 02 Dec 2016
At a glance
- Drugs TT 034 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; First in man
- Sponsors Tacere Therapeutics
- 28 Nov 2016 Status changed from active, no longer recruiting to completed.
- 03 May 2016 Status changed from recruiting to active, no longer recruiting.
- 25 Apr 2016 Interim results published in the Benitec media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History